Allspring Global Investments Holdings LLC Has $111.18 Million Stake in Hologic, Inc. $HOLX

Allspring Global Investments Holdings LLC lifted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 473.5% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 1,701,820 shares of the medical equipment provider’s stock after buying an additional 1,405,085 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Hologic were worth $111,180,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of HOLX. Greenleaf Trust grew its position in Hologic by 5.1% in the 2nd quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider’s stock valued at $233,000 after purchasing an additional 173 shares during the period. Beverly Hills Private Wealth LLC grew its position in Hologic by 3.6% in the 1st quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider’s stock valued at $320,000 after purchasing an additional 180 shares during the period. Allworth Financial LP grew its position in Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 216 shares during the period. First American Bank grew its position in Hologic by 0.9% in the 2nd quarter. First American Bank now owns 28,705 shares of the medical equipment provider’s stock valued at $1,870,000 after purchasing an additional 245 shares during the period. Finally, SPC Financial Inc. grew its position in Hologic by 2.2% in the 2nd quarter. SPC Financial Inc. now owns 12,859 shares of the medical equipment provider’s stock valued at $838,000 after purchasing an additional 278 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on HOLX shares. Wall Street Zen downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Morgan Stanley lifted their price target on shares of Hologic from $65.00 to $69.00 and gave the company an “equal weight” rating in a research report on Thursday, July 31st. Stephens reissued an “overweight” rating and issued a $78.00 price target on shares of Hologic in a research report on Thursday, September 18th. Weiss Ratings restated a “hold (c-)” rating on shares of Hologic in a research note on Wednesday, October 8th. Finally, Argus raised their price objective on Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a research note on Friday, September 19th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $80.15.

Insider Activity at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the sale, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. The trade was a 10.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.88% of the stock is owned by insiders.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $65.51 on Tuesday. The stock has a market cap of $14.57 billion, a PE ratio of 27.18, a price-to-earnings-growth ratio of 2.32 and a beta of 0.63. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.39. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The stock’s fifty day simple moving average is $67.10 and its two-hundred day simple moving average is $63.36.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period in the previous year, the business posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.